![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 46, 32875-32880, November 12, 1999
§,
,
,
,
,
, and
From
UMR CNRS 6547, Université Blaise Pascal,
Les Cézeaux, 63177 Aubière, Cedex, France and
¶ URA31 CNRS, Université Louis Pasteur,
67000 Strasbourg, France
| |
ABSTRACT |
|---|
|
|
|---|
Mouse vas deferens protein (MVDP) is an aldose
reductase-like protein that is highly expressed in the vas deferens and
adrenal glands and whose physiological functions were unknown. We
hereby describe the enzymatic characteristics of MVDP and its role in murine adrenocortical Y1 cells. The murine aldose reductase (AR) and
MVDP cDNAs were expressed in bacteria to obtain recombinant proteins and to compare their enzymatic activities. Recombinant MVDP
was functional and displayed kinetic properties distinct from those of
murine AR toward various substrates, a preference for NADH, and
insensitivity to AR inhibitors. For MVDP, isocaproaldehyde, a product
of side-chain cleavage of cholesterol generated during steroidogenesis,
is the best natural substrate identified so far. In Y1 cells, we found
that NADH-linked isocaproaldehyde reductase (ICR) activity was much
higher than NADPH-linked ICR activity and was not abolished by AR
inhibitors. We demonstrate that in Y1 cells, forskolin-induced MVDP
expression enhanced NADH-linked ICR activity by 5-6-fold, whereas no
variation in ICR-linked NADPH activity was observed in the same
experiment. In cells stably transfected with MVDP antisense cDNA,
NADH-linked ICR activity was abolished even in the presence of
forskolin, and the isocaproaldehyde toxicity was increased compared
with that of intact Y1 cells, as measured by isocaproaldehyde
LD50. In Y1 cells transfected with MVDP antisense
cDNA, forskolin-induced toxicity was abolished by
aminoglutethimide. These results indicate that in adrenocortical cells,
MVDP is responsible for detoxifying isocaproaldehyde generated by steroidogenesis.
Aldoketoreductases
(AKRs)1 are monomeric
oxidoreductases that catalyze the NADPH-dependent
conversion of aldehydes and ketones to their corresponding alcohols
(1). Among the AKR superfamily, aldose reductase (AR) has been a focus
of interest because of its potential role in the development of
secondary diabetic complications (2). In agreement with its broad
substrate specificity, AR is thought to accomplish varying
physiological roles in osmotic homeostasis (3), steroid conversion (4),
and detoxification against xenobiotic and endogenous aldehydes (5). To
date, the AKR superfamily consists of at least 42 members that differ
in their primary structure, substrate specificities, and catalytic properties.
Adult mouse vas deferens contains a large amount of a major protein
(mouse vas deferens protein (MVDP)) with an apparent molecular mass of
34,500 Da (6). Recently, it has been shown that MVDP expression is not
restricted to the vas deferens, and high levels of MVDP mRNA were
found in the adrenal glands (7). Androgens have been shown to be the
primary regulating factors of MVDP expression in the vas deferens (8);
and recent studies suggest that cAMP is a key regulator of adrenal MVDP
expression (9). MVDP shares ~70% amino acid identity with human,
rabbit, rat, and mouse ARs (10, 11), and MVDP gene structure is similar
to that of the human AR gene (12). However, MVDP is more closely
related to the mouse fibroblast growth factor-regulated protein FR-1
(13), Chinese hamster ovary reductase (14), the human AR-like gene ALR1 (15), and human small intestine reductase (16). These proteins share ~80-90% sequence identities and form a distinct subgroup within the AKR1B group according to the new nomenclature proposed by Jez et al. (17). The enzymatic nature of MVDP
(AKR1B7 in agreement with the proposed nomenclature (17)) has not yet been demonstrated.
In this study, we have compared the enzymatic characteristics and
substrate specificity of MVDP with those of mAR, and we have focused on
its physiological role in adrenal glands. The data indicate that MVDP
acts as a major reductase for isocaproaldehyde formed during steroidogenesis.
Chemicals--
Tolrestat was a gift from Wyet-Ayerst, Sorbinil
from Pfizer, and Imirestat from Alcon Laboratories. Isocaproaldehyde
was prepared according to the method of Matsuura et al.
(18). 4-Hydroxynonenal was provided by Interchim. All other chemicals
were purchased from Sigma.
Recombinant Protein Production--
MVDP and mAR cDNAs were
obtained by polymerase chain reaction amplification with MVDP pUC13
(10) and mAR pGEMT (pmAR13) (11) as templates, respectively, and with
outside primers containing engineered 5'- BamHI and
3'-EcoRI sites (5'-BamHI primer,
5'-GCAGGATCCATGGCCACCTTCGTGGAACTC-3'; and 3'-EcoRI primer,
5'-ATTGAATTCTCAGTGTTACCATACTACATGC-3'). Recombinant MVDP and mAR
were expressed in Escherichia coli by inserting their respective cDNAs into the BamHI and EcoRI
sites of pET28a (Novagen) to produce N-terminal fusions with six
histidine residues. Recombinant MVDP and mAR were produced in BL21(DE3)
pLysS cells upon isopropyl- Y1 Cell Lines Expressing MVDP Antisense RNA by Stable
Transfection--
The pCR3 vector (Invitrogen) harboring the neomycin
resistance gene was used to express MVDP antisense RNA in murine
adrenocortical Y1 cells (19) in stable transfection experiments. The
complete MVDP cDNA was obtained by XbaI/EcoRI
digestion of pET-MVDP and inserted in antisense orientation in pCR3.
This construct was named pCR3-AS. Y1 cells were transfected with either
5 µg of pCR3-AS or pCR3-EV (empty control plasmid) vector by
lipofection using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium
salts (Roche Molecular Biochemicals). After a 48-h recovery period, 400 µg/ml G418 was added to the medium. G418-resistant cells were
selected, isolated by limiting dilution, and then propagated. Cellular
clones harboring either the pCR3-AS or pCR3-EV vector were named AS and EV cells, respectively. The presence of the pCR-AS vector (6.3 kilobases) in the neomycin-resistant selected Y1 cells was identified by Southern blot analysis after EcoRI digestion of cellular
genomic DNA. The Southern blot was hybridized with a MVDP probe
(1226-base pair XbaI/EcoRI fragment covering the
complete MVDP cDNA) labeled by random priming.
Cell and Tissue Extracts--
Y1 cells were routinely cultured
as described previously in Dulbecco's modified Eagle's
medium/nutrient mixture F-12 supplemented with 10% fetal calf serum
(9). AS or EV stably transfected Y1 cellular clones were routinely
cultured in the same medium containing 200 µg/ml G418. 24 h
prior to treatment with various hormones or drugs, G418 was removed.
Human H295R adrenocortical cells were cultured as described previously
(9). 24 h before harvest, cells were cultured under basal
conditions or in the presence of 10 Enzymatic Assay--
The standard reaction mixture for the
reductase activities contained 0.1 M sodium phosphate
buffer (pH 6.6), 0.4 M ammonium sulfate, and appropriate
amounts of NAD(P)H, substrate, and enzyme or protein extracts as
indicated for each experiment. The reaction was carried out at
25 °C, and the decrease in NAD(P)H was monitored by
spectrophotometer at 340 nm. Reactions were routinely started by the
addition of enzyme or protein extracts. Controls without substrate or
without enzyme were run simultaneously. One enzyme unit is defined as
the change at 340 nm corresponding to the oxidation of 1 µmol of NAD(P)H.
Northern Blot Analysis--
Northern bolt analysis of total RNAs
isolated from Y1 cells was performed according to the method previously
described (9).
Western Blot Analysis--
Frozen cell or tissue samples were
homogenized in 250 mM Tris-HCl (pH 7.5) and 0.4 mM phenylmethylsulfonyl fluoride. Soluble tissue or cell
extracts (20 µg of proteins) or recombinant MVDP or AR was subjected
to SDS-PAGE or NEpHGE and transferred to nitrocellulose membranes.
Blots were treated as previously described (9) and then incubated with
either primary anti-MVDP monoclonal antibody (ascites B263) at a 1:700
dilution or rabbit anti-rat AR serum at a 1:3000 dilution for 1 h
at room temperature. When NEpHGE was performed, blots were treated with
primary rabbit anti-MVDP serum at 1:5000 dilution.
Peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies
were added at a 1:15,000 dilution for 1 h at room temperature.
Peroxidase activity was detected with the enhanced chemiluminescence
system (ECL, Amersham Pharmacia Biotech).
Forskolin and Isocaproaldehyde Toxicity Measurement--
Stably
transfected Y1 cellular clones (AS19 or EV4 cells) were plated in 1 ml
of fresh medium in 2-cm2 culture wells at a concentration
of 5 × 104 cells/ml. After a recovery period, cells
were cultured under basal conditions or with 10 Statistics--
Results are given as means ± S.D.
Statistical significance of the differences between treatment groups
was determined by Student's t test.
Kinetic Properties of Recombinant MVDP--
To compare the
enzymatic activities and substrate specificity of MVDP with those of
mAR, both cDNAs were expressed in bacteria to obtain recombinant
proteins. The kinetic constants of both proteins, determined for
various substrates, are summarized in Table
I. Similar to native AR purified from
tissues, recombinant mAR has the ability to reduce aldo sugars,
glyceraldehyde being the best substrate among them. Except for
relatively lower Km values with glucose, values for
recombinant mAR were in accordance with those reported for AR isolated
from other species (20-23). By comparison with other compounds,
isocaproaldehyde, methylglyoxal, and 4-hydroxynonenal were the best
substrates. MVDP showed kinetic properties distinct from those of mAR.
As shown in Table I, common substrates for AKR, including aldo sugars,
were poor substrates for recombinant MVDP. For all compounds studied,
the kcat values were always lower than those
measured for mAR (Table I), even tested under various pH conditions
(data not shown). Aldose reductases are able to use NADPH and also
NADH, but with less efficiency (24-26). Other AKRs such as aldehyde or
carbonyl reductases display a strict NADPH-dependent
activity (27, 28). To determine the MVDP requirements for its cofactor,
we also determined the kinetic constants for MVDP with NADH as a
cofactor. When NADH was used instead of NADPH, the
kcat values were 2-5-fold higher than those measured using NADPH, indicating that MVDP has a strong preference for
NADH. Even though this enzyme shows a strong affinity for 4-hydroxynonenal, on the basis of comparison of the catalytic efficiencies (kcat), isocaproaldehyde seems to
be the preferred substrate catalyzed by MVDP. Table
II lists the effects of various compounds
known as inhibitors of AR. Recombinant MVDP was not inhibited by
Sorbinil and p-chloromercuribenzoate and was moderately diminished by Imirestat and Tolrestat, differing in this respect from
recombinant mAR.
MVDP Reduces Isocaproaldehyde in Adrenocortical
Cells--
Isocaproaldehyde, the best substrate identified for MVDP,
is a product of the side-chain cleavage of cholesterol, the first step
of steroid biosynthesis. On the basis of Western blot analysis, both
MVDP and AR were detected in adrenal glands. By comparison with known
amounts of recombinant proteins, the concentrations of MVDP and AR were
found to be very similar, ~1% of total soluble proteins (Fig.
1). It has been shown that in murine
adrenocortical cells, MVDP expression is up-regulated by forskolin (9).
If isocaproaldehyde is reduced by MVDP in adrenocortical cells, it would be predicted that isocaproaldehyde reductase (ICR) activity should be enhanced by the addition of forskolin. However, since AR has
been described as a major reductase for isocaproaldehyde in adrenal
glands (18), we have developed a test to discriminate between AR and
MVDP ICR activities. As shown in Fig. 2,
treatment of Y1 cells for 24 h with 10 MVDP Antisense cDNA Abolishes NADH-linked ICR Activity in
Adrenocortical Cells--
Besides MVDP, the AKR1B subgroup contains
proteins such as FR-1 (13) and human small intestine reductase (16),
which are expressed in adrenal glands. To better understand the role of MVDP in adrenal glands, Y1 cells were stably transfected with the pCR3
vector containing MVDP antisense cDNA to prevent MVDP expression or
with the empty vector as a control. Nine positive clones stably
transfected with the pCR3 vector containing antisense cDNA and 12 clones transfected with the empty vector were selected after Southern
blot analysis (data not shown). As expected, high levels of MVDP (Fig.
3) and strong NADH-linked ICR activity
(Table IV) were observed after forskolin
treatment in Y1 cells transfected with the empty vector (EV2 and EV4
cells). In contrast, MVDP and its mRNA were undetectable in Y1
cells transfected with MVDP antisense cDNA (AS19 cells) cultured
either under basal conditions or with forskolin (Fig. 3, A
and B). As MVDP and mAR display high homology in their
nucleotide sequences, the presence of intact mAR protein levels was
checked in these clones. As shown in Fig. 3A, mAR levels were not altered by MVDP antisense mRNA. In Y1 cells, in which antisense RNA completely abolishes MVDP expression (AS19 cells), no
NADH-linked ICR was detected, indicating that ICR activity in adrenal
glands is due mainly to MVDP (Table IV). Because basal NADH-linked ICR
activity was totally blocked in AS19 cells, the presence of MVDP in EV4
cells cultured under basal conditions was checked to account for its
involvement in NADH-linked ICR activity. Immunodetection using a highly
titrated rabbit anti-MVDP antiserum demonstrated the presence of MVDP
in EV4 cells cultured under basal conditions, whereas no MVDP
expression was detected in AS19 cells cultured in the presence of
forskolin (Fig. 3C).
Forskolin and Isocaproaldehyde Toxicity Measurement--
Because
forskolin is a potent activator of steroidogenesis in Y1 cells and
therefore a potent activator of isocaproaldehyde production, we
measured the viability of AS19 cells lacking MVDP ICR activity when
treated with forskolin alone or with aminoglutethimide, an inhibitor of
the first step of steroid synthesis.
The viability of MVDP-nonexpressing AS19 cells was significantly
reduced after a 24-h forskolin exposure compared with EV4 cells (Fig.
4), and this effect was totally blocked
when aminoglutethimide was simultaneously added to the medium,
suggesting that forskolin is not toxic by itself, but works rather by
stimulating the endogenous production of isocaproaldehyde through the
enhancement of P450scc activity.
LD50 was determined in EV4 and AS19 cells by adding
increasing amounts of exogenous isocaproaldehyde (Fig.
5). Under our experimental conditions,
LD50 was significantly decreased from 4.9 to 3 mM in cells lacking MVDP, demonstrating that MVDP ICR
activity is important for detoxifying isocaproaldehyde.
Isocaproaldehyde Reductase Activity in H295R Cell Line--
As
MVDP was also previously described to be expressed under forskolin
control in the human adrenocortical H295R cell line (9), ICR activity
was therefore investigated under the same experimental conditions
described for Y1 cells (Table V). In H295R cells, as observed in Y1 cells, NADH-linked ICR activity was
higher than NADPH-linked activity and was also enhanced by forskolin
treatment, suggesting that in human adrenocortical cells, MVDP ICR
activity is also required for detoxifying isocaproaldehyde.
Here we demonstrate that recombinant MVDP was active when tested
with a variety of common substrates for AR. However, MVDP displayed
kinetic properties distinct from those of classical AR. 1) MVDP has a
strong preference for NADH; and 2) its enzymatic activity was highly
insensitive to most AR inhibitors tested. Based on amino acid sequence
identities, MVDP is more homologous to FR-1 (13), CHO reductase (14),
ALR1 (15), and human small intestine reductase (16) than to
AR (11). The kinetic properties determined for some of these enzymes
indicate that they have different enzymatic activities over a range of
substrates. This observation contrasts with the apparent conservation
of the amino acid residues known to be involved in AR enzymatic
activities. The key amino acids proposed to be involved in hydrogen
transfer in AR (Tyr48, Asp43,
Lys77, and Hist110) (23, 29, 30) and the 18 residues reported to interact with NADPH (Thr19,
Trp20, Lys21, Asp43,
Ser159, Asn160, Glu183,
Tyr209, Ser210, Leu212,
Ser214, Lys262, Ser263,
Val264, Thr265, Arg268,
Glu271, and Asn272) (31) are conserved within
the five sequences, except a Glu at position 21 in CHO reductase. It
has been shown that deletion of the last 13 amino acid residues at the
C-terminal end of AR decreased catalytic effectiveness, suggesting that
this region is crucial to proper orientation of substrates in the
active pocket site (32). The C-terminal domains were more divergent
among mAR, FR-1, CHO reductase, ALR1, human small intestine
reductase, and MVDP, suggesting that these enzymes exhibit different
substrate specificities in relation to their tissue distribution.
Whereas AR is present in many tested tissues, expression of MVDP, FR-1,
CHO reductase, ALR1, and human small intestine reductase is
restricted to a limited number of tissues. Some of these proteins have
been shown to be induced by different factors, including hyperosmotic
stress or an excess of galactose (AR) (3, 33), growth factors (FR-1)
(13), chemical factors (CHO reductase) (14), or hormonal factors (MVDP)
(8, 9). At present, it is not known whether ALR1 and human
small intestine reductase, the human homologs, are also inducible.
Then, the differences observed in kinetic properties, pattern of
expression, and mechanisms of induction indicate that all these related
proteins are probably involved in different physiological functions.
The first step of steroidogenesis is the removal of the cholesterol
side chain, resulting in the formation of pregnenolone and
isocaproaldehyde (4-methylpentanal), which is metabolized to isocaproic
acid and isocapryl alcohol (34). 4-Hydroxynonenal is a reactive
aldehyde formed via peroxidative damage to polyunsaturated fatty acids in membrane phospholipids (35). On the basis of the catalytic efficiencies obtained with various substrates, isocaproaldehyde and
4-hydroxynonenal seem to be the preferred substrates catalyzed by
recombinant MVDP. Since MVDP and mAR were expressed in similar amounts
in adrenal glands, both enzymes may be responsible for the reduction of
isocaproaldehyde and 4-hydroxynonenal generated by cellular metabolism.
However, several lines of evidence suggest that MVDP, rather than AR,
is a major reductase for isocaproaldehyde in murine adrenocortical
cells. First, NADH-linked ICR activity (ascribed to MVDP) was higher
than NADPH-linked ICR activity (attributed to AR). Second, NADH-linked
ICR activity was not inhibited by specific AR inhibitors. Third,
NADH-linked ICR activity was strongly enhanced by forskolin, which
stimulates MVDP expression, but not by hyperosmotic stress inducing AR
overexpression. Fourth, in Y1 cells stably transfected with MVDP
antisense cDNA, NADH-linked ICR activity induced by forskolin was
completely abolished. Our results differ from those of Matsuura
et al. (18), who have shown that in human, monkey, dog, and
rabbit adrenal glands, AR is a major reductase for isocaproaldehyde;
but both NADH- and NADPH-linked ICR activities measured in the
experiments of Matsuura et al. (18) are lower than those
from our assay in cytosolic extracts. Some of the possible reasons for
these dissimilar results include differences concerning species and
experimental procedures. ICR activity has been previously measured in
frozen adrenal extracts; in this study, we used fresh extracts of
intact adrenal glands and fresh extracts of adrenocortical Y1 cells.
Strikingly, in vitro kcat/Km
values suggest that mAR/NADPH at equal concentration as is found in
adrenal glands should be the main isocaproaldehyde reductase. Ex
vivo experiments in Y1 cells contrast with this observation,
suggesting that when produced in vitro from a bacterial
expression system, MVDP is in a less effective state than when produced
endogenously. In agreement with the observations of Grimshaw et
al. (36) that activated or oxidized forms of human placenta aldose
reductase result in an increase in Km, a net
decrease in kcat/Km for
DL-glyceraldehyde, and an insensitivity to Sorbinil
inhibition, one possibility could be that in vitro produced
MVDP exists in an oxidized form. Similarly, in Y1 cells lacking MVDP,
NADH-linked 4-hydroxynonenal reductase activity is strongly reduced
(data not shown). The results suggest that one function for MVDP,
rather than mAR, in adrenocortical cells may be detoxification for
protection against endogenous harmful aldehydes, including
isocaproaldehyde and 4-hydroxynonenal. The biosynthesis of steroids is
acutely and chronically stimulated by trophic hormones through the
intermediary of cAMP (37). Interestingly, chronic effects of trophic
hormones result from increased transcription of the genes that encode
the steroidogenic enzymes (37) as well as MVDP (9), thereby maintaining
optimal capacity for both steroid production and reduction of
isocaproaldehyde. Immunodetection of MVDP in Leydig cell
cultures2 suggests that MVDP
plays this role in other steroidogenic cells.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-thiogalactopyranoside induction and purified by nickel affinity chromatography according to
the manufacturer's instructions (Novagen). For each protein, column
fractions were analyzed by SDS-PAGE, and those containing the purified
protein were pooled and stored at 4 °C.
5 M
forskolin or 75 mM NaCl. Adrenal glands were removed from
adult male CD1 mice. Tissues or cells were immediately homogenized in 0.1 M sodium phosphate buffer (pH 6.6) containing 1 mM dithiothreitol. The homogenates were centrifuged at
105,000 × g for 1 h, and the supernatants were
collected and immediately used for enzymatic assay or subsequent
SDS-PAGE analysis.
5
M forskolin alone or with 5 × 10
4
M aminoglutethimide for 24 h. When the
LD50 of isocaproaldehyde was assayed, cells were exposed to
increasing concentrations of isocaproaldehyde for 4 h. After
treatments, cells were resuspended, and their viability was immediately
estimated by 0.2% (w/v) trypan blue exclusion.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Kinetic constants for recombinant mAR and MVDP
Effect of inhibitors on recombinant mAR and MVDP
5
M forskolin strongly increased MVDP expression, whereas a
24-h exposure of the cells to hypertonic medium had no effect on MVDP levels. Conversely, AR levels were not affected by forskolin and were
enhanced after exposure to hypertonic medium. As shown in Table
III, no variation in NADPH-linked ICR
activity was observed in cells stimulated by forskolin or exposed to
hypertonic medium. When we used NADH instead of NADPH, a strong
activity was measured in unstimulated cells. No stimulating effect was
observed in cells exposed to hypertonic medium; however, when cells
were exposed to forskolin treatment, NADH-linked ICR activity was
strongly enhanced (~5-fold), and this effect was not abolished by the
presence of Sorbinil and correlated with forskolin-induced MVDP
expression. Similar experiments showed that NADH-linked
4-hydroxynonenal reductase activity was higher than NADPH-linked
4-hydroxynonenal reductase activity, but was not increased after
forskolin exposure (Table III). Using the same experimental procedures,
NADH-linked ICR activity in adult murine adrenal cytosolic extracts was
estimated to ~150 µmol/min/mg of protein, and NADPH-linked ICR
activity was determined to ~25 µmol/min/mg of protein extract.

View larger version (61K):
[in a new window]
Fig. 1.
MVDP and mAR levels in adrenal glands.
Equivalent amounts of recombinant MVDP (A) or mAR
(B) and 10 µg of total soluble adrenal proteins were
subjected to SDS-PAGE and Western blot analysis using either an
anti-MVDP monoclonal antibody or an anti-AR polyclonal antiserum.

View larger version (60K):
[in a new window]
Fig. 2.
Effect of forskolin and hyperosmotic stress
on MVDP and mAR protein levels in adrenocortical Y1 cells. Cell
cultures were untreated or treated with either forskolin- or hypertonic
NaCl-supplemented medium for 24 h. Cell extracts were prepared,
and 20 µg of cytosolic soluble proteins were subjected to SDS-PAGE
and Western blotting using either an anti-AR polyclonal antiserum
(A) or an anti-MVDP monoclonal antibody
(B).
ICR and 4-hydroxynonenal reductase activities in the murine
adrenocortical Y1 cell line

View larger version (50K):
[in a new window]
Fig. 3.
Effect of MVDP antisense RNA on MVDP and mAR
expression in neomycin-resistant Y1 cellular clones. Cellular
clones stably transfected with pCR3-AS encoding MVDP antisense RNA
(AS19) or with pCR3-EV (empty vector; EV2 and EV4) were treated with
either forskolin (A and B) or NaCl
(A). A, 20 µg of cytosolic proteins were
subjected to SDS-PAGE and Western blotting as described in the legends
to Figs. 1 and 2. B, RNA was isolated, and equivalent
amounts of each sample (25 µg) were analyzed by Northern blot
hybridization using 32P-labeled MVDP or
-actin cDNA
probes. C, 200 µg of cytosolic proteins from AS19 or EV4
cells cultured with or without 10
5 M
forskolin, respectively, were subjected to NEpHGE (NEpHGE)
and Western blotting using a highly titrated anti-MVDP polyclonal
antiserum. Arrows indicate the position of the MVDP
corresponding migration spot. The two other spots correspond to
cross-reacting proteins unrelated to MVDP.
NADH- and NADPH-linked ICR activities in Y1 clones expressing or not
MVDP antisense RNA

View larger version (48K):
[in a new window]
Fig. 4.
Effect of aminoglutethimide on
forskolin-induced cell toxicity. Subconfluent EV4 or AS19 cells
were treated with forskolin- and aminoglutethimide-supplemented medium
for 24 h. After treatments, cell viability was estimated by trypan
blue exclusion. Values are means ± S.D. of at least 12 experiments. *, significantly different from control (p < 0. 01).

View larger version (22K):
[in a new window]
Fig. 5.
LD50 of isocaproaldehyde.
Subconfluent EV4 and AS19 cells were treated with increasing
isocaproaldehyde concentrations for 4 h. After treatments, cell
viability was estimated as described in the legend to Fig. 4. Values
are means ± S.D. of at least 12 experiments. *, significantly
different from values obtained for EV4 cells exposed to the same
isocaproaldehyde concentration (p < 0. 01).
Isocaproaldehyde reductase activity in the human H295R cell line
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. D. A. Carper for the gift of the rabbit anti-rat aldose reductase antiserum. We are especially grateful to Dr. Veschambre for preparing isocaproaldehyde. We thank Drs. Jean-François Biellmann, Alain Van Dorsselaer, Alberto Podjarny, Patrick Barth, Hélène Rogniaux, and Benoit Viollet for helpful discussions and advice. We thank Dr. Laurent Morel for critical reading of the text. We thank Alain Halère and Jean-Paul Saru for technical assistance.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence and reprint requests should be addressed. Tel.: 4-73-40-77-59; Fax: 4-73-40-70-42; E-mail: martinez@cicsun. univ-bpclermont.fr.
2 A.-M. Lefrançois-Martinez, C. Tournaire, A. Martinez, M. Berger, S. Daoudal, D. Tritsch, G. Veyssière, and C. Jean, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: AKRs, aldoketoreductases; AR, aldose reductase; mAR, murine aldose reductase; MVDP, mouse vas deferens protein; PAGE, polyacrylamide gel electrophoresis; ICR, isocaproaldehyde reductase; CHO, Chinese hamster ovary.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bohren, K. M.,
Bullock, B.,
Wermuth, B.,
and Gabbay, K. H.
(1989)
J. Biol. Chem.
264,
9547-9551 |
| 2. | Gabbay, K. H. (1975) Annu. Rev. Med. 26, 521-536[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Bagnasco, S.,
Balaban, R.,
Fales, H.,
Yang, Y. M.,
and Burg, M.
(1986)
J. Biol. Chem.
261,
5872-5877 |
| 4. | Warren, J. C., Murdock, G. L., Ma, Y., Goodman, S. R., and Zimmer, W. E. (1993) Biochemistry 32, 1401-1406[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Grimshaw, C. E. (1992) Biochemistry 31, 10139-10145[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Taragnat, C., Berger, M., and Jean, C. (1988) J. Reprod. Fert. 83, 835-842[Abstract] |
| 7. | Lau, E., Cao, D., Lin, C., Chung, S. K., and Chung, S. S. (1995) Biochem. J. 312, 609-615 |
| 8. | Martinez, A., Pailhoux, E., Berger, M., and Jean, C. (1990) Mol. Cell. Endocrinol. 72, 201-211[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Aigueperse, C., Martinez, A., Lefrançois-Martinez, A.-M., Veyssière, G., and Jean, C. (1998) J. Endocrinol. 160, 147-154 |
| 10. |
Pailhoux, E.,
Martinez, A.,
Veyssière, G.,
and Jean, C.
(1990)
J. Biol. Chem.
265,
19932-19936 |
| 11. | Daoudal, S., Berger, M., Pailhoux, E., Tournaire, C., Veyssière, G., and Jean, C. (1995) Life Sci. Adv. (Steroid Biochem.) 14, 45-58 |
| 12. | Pailhoux, E., Veyssière, G., Fabre, S., Tournaire, C., and Jean, C. (1992) J. Steroid Biochem. Mol. Biol. 42, 561-568[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Donohue, P. J.,
Alberts, G. F.,
Hampton, B.,
and Winkles, J. A.
(1994)
J. Biol. Chem.
269,
8604-8609 |
| 14. |
Hyndman, D. J.,
Takenoshita, R.,
Vera, N. L.,
Pang, S. C.,
and Flynn, T. G.
(1997)
J. Biol. Chem.
272,
13286-13291 |
| 15. |
Cao, D.,
Fan, S. T.,
and Chung, S. S. M.
(1998)
J. Biol. Chem.
273,
11429-11435 |
| 16. | Hyndman, D. J., and Flynn, T. G. (1998) Biochim. Biophys. Acta 1399, 198-202[Medline] [Order article via Infotrieve] |
| 17. | Jez, J. M., Flynn, T. G., and Penning, T. M. (1997) Biochem. Pharmacol. 54, 639-647[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Matsuura, K., Deyashiki, Y., Bunai, Y., Ohya, I., and Hara, A. (1996) Arch. Biochem. Biophys. 328, 265-271[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Yasumura, Y., Buonassisi, V., and Sato, G. (1966) Cancer Res. 26, 529-535[Medline] [Order article via Infotrieve] |
| 20. | Iwata, N., Inazu, N., and Satoh, T. (1990) Arch. Biochem. Biophys. 282, 70-77[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Nishimura, C., Yamaoka, T., Mizutami, M., Yamashita, K., Akera, T., and Tanimoto, T. (1991) Biochim. Biophys. Acta 1078, 171-178[Medline] [Order article via Infotrieve] |
| 22. |
Bohren, K. M.,
Page, J. L.,
Shankar, R.,
Henry, S. P.,
and Gabbay, K. H.
(1991)
J. Biol. Chem.
266,
24031-24037 |
| 23. | Carper, D. A., Hohman, T. C., and Old, S. E. (1995) Biochim. Biophys. Acta 1246, 67-73[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Boghosian, R. A., and McGuiness, E. T. (1979) Biochim. Biophys. Acta 567, 278-286[Medline] [Order article via Infotrieve] |
| 25. | Hadler, A. B., and Crabbe, M. J. C. (1984) Biochem. J. 219, 33-39[Medline] [Order article via Infotrieve] |
| 26. | Wermuth, B., Bürgisser, H., Bohren, K., and Von Wartburg, J. P. (1982) Eur. J. Biochem. 127, 279-284[Medline] [Order article via Infotrieve] |
| 27. | Turner, A. J., and Tipton, K. F. (1972) Biochem. J. 130, 765-772[Medline] [Order article via Infotrieve] |
| 28. |
Wermuth, B.,
Münch, J. D. B.,
and Von Wartburg, J. P.
(1977)
J. Biol. Chem.
252,
3821-3828 |
| 29. |
Tarle, I.,
Borhani, D. W.,
Wilson, D. K.,
Quiocho, F. A.,
and Petrash, J. M.
(1993)
J. Biol. Chem.
268,
25687-25693 |
| 30. | Bohren, K. M., Grimshaw, C. E., Lay, C. J., Harrisson, D. J., Ringe, D., Petsko, G. A., and Gabbay, K. H. (1994) Biochemistry 33, 2021-2032[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Wilson, D. K.,
Bohren, K. M.,
Gabbay, K. H.,
and Quiocho, F. A.
(1992)
Science
257,
81-84 |
| 32. |
Petrash, J. M.,
Harter, T. M.,
Devine, C. S.,
Olins, P. O.,
Bhatnagar, A.,
Lui, S.,
and Srivastava, S. K.
(1992)
J. Biol. Chem.
267,
24833-24840 |
| 33. | Bekhor, I., Shi, S., and Unakar, N. J. (1990) Mol. Cell. Biochem. 95, 55-60[Medline] [Order article via Infotrieve] |
| 34. | Hall, P. F. (1970) in in The Testis (Johnson, A. D. , Gomes, W. R. , and Vandemark, N. L., eds) , pp. 1-72, Academic Press, New York |
| 35. | Esterbauer, H., Schaur, R. J., and Zollner, H. (1991) Free Radical Biol. Med. 11, 81-128[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Grimshaw, C. E, Bohren, K. M., Lai, C. J., and Gabbay, K. H. (1995) Biochemistry 34, 14366-14373[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Simpson, E. R., and Waterman, E. R. (1988) Annu. Rev. Physiol. 50, 427-440[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
C Baumann, B Davies, M Peters, U Kaufmann-Reiche, M Lessl, and F Theuring AKR1B7 (mouse vas deferens protein) is dispensable for mouse development and reproductive success Reproduction, July 1, 2007; 134(1): 97 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tirard, J. Gout, A. M. Lefrancois-Martinez, A. Martinez, M. Begeot, and D. Naville A Novel Inhibitory Protein in Adipose Tissue, the Aldo-Keto Reductase AKR1B7: Its Role in Adipogenesis Endocrinology, May 1, 2007; 148(5): 1996 - 2005. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Battista, C. Roberge, M. Otis, and N. Gallo-Payet Seladin-1 expression in rat adrenal gland: effect of adrenocorticotropic hormone treatment J. Endocrinol., January 1, 2007; 192(1): 53 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. O. Ward, D. A. Delker, S. D. Hester, S.-F. Thai, D. C. Wolf, J. W. Allen, and S. Nesnow Transcriptional Profiles in Liver from Mice Treated with Hepatotumorigenic and Nonhepatotumorigenic Triazole Conazole Fungicides: Propiconazole, Triadimefon, and Myclobutanil Toxicol Pathol, December 1, 2006; 34(7): 863 - 878. [Abstract] [PDF] |
||||
![]() |
B. Ragazzon, A.-M. Lefrancois-Martinez, P. Val, I. Sahut-Barnola, C. Tournaire, C. Chambon, J.-L. Gachancard-Bouya, R.-J. Begue, G. Veyssiere, and A. Martinez Adrenocorticotropin-Dependent Changes in SF-1/DAX-1 Ratio Influence Steroidogenic Genes Expression in a Novel Model of Glucocorticoid-Producing Adrenocortical Cell Lines Derived from Targeted Tumorigenesis Endocrinology, April 1, 2006; 147(4): 1805 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Azuma, T. Nishinaka, S. Ushijima, J. Soh, M. Katsuyama, H.-P. Lu, M. Kawata, C. Yabe-Nishimura, and T. Miki Characterization of htAKR, a novel gene product in the aldo-keto reductase family specifically expressed in human testis Mol. Hum. Reprod., July 1, 2004; 10(7): 527 - 533. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Lefrancois-Martinez, J. Bertherat, P. Val, C. Tournaire, N. Gallo-Payet, D. Hyndman, G. Veyssiere, X. Bertagna, C. Jean, and A. Martinez Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3010 - 3019. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Volle, J. J. Repa, A. Mazur, C. L. Cummins, P. Val, J. Henry-Berger, F. Caira, G. Veyssiere, D. J. Mangelsdorf, and J.-M. A. Lobaccaro Regulation of the Aldo-Keto Reductase Gene akr1b7 by the Nuclear Oxysterol Receptor LXR{alpha} (Liver X Receptor-{alpha}) in the Mouse Intestine: Putative Role of LXRs in Lipid Detoxification Processes Mol. Endocrinol., April 1, 2004; 18(4): 888 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Val, C. Aigueperse, B. Ragazzon, G. Veyssiere, A.-M. Lefrancois-Martinez, and A. Martinez Adrenocorticotropin/3',5'-Cyclic AMP-Mediated Transcription of the Scavenger akr1-b7 Gene in Adrenocortical Cells Is Dependent on Three Functionally Distinct Steroidogenic Factor-1-Responsive Elements Endocrinology, February 1, 2004; 145(2): 508 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Martinez, P. Val, I. Sahut-Barnola, C. Aigueperse, G. Veyssiere, and A.-M. Lefrancois-Martinez Steroidogenic Factor-1 Controls the Aldose Reductase akr1b7 Gene Promoter in Transgenic Mice through an Atypical Binding Site Endocrinology, May 1, 2003; 144(5): 2111 - 2120. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Val, A. Martinez, I. Sahut-Barnola, C. Jean, G. Veyssiere, and A.-M. Lefrancois-Martinez A 77-Base Pair LINE-Like Sequence Elicits Androgen-Dependent mvdp/akr1-b7 Expression in Mouse Vas Deferens, But Is Dispensable for Adrenal Expression in Rats Endocrinology, September 1, 2002; 143(9): 3435 - 3448. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kobayashi, T. Kaneko, Y. Iuchi, S. Matsuki, M. Takahashi, I. Sasagawa, T. Nakada, and J. Fujii Localization and Physiological Implication of Aldose Reductase and Sorbitol Dehydrogenase in Reproductive Tracts and Spermatozoa of Male Rats J Androl, September 1, 2002; 23(5): 674 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sarkar, T. Imai, F. Kambe, A. Shibata, S. Ohmori, A. Siddiq, S. Hayasaka, H. Funahashi, and H. Seo The Human Homolog of Diminuto/Dwarf1 Gene (hDiminuto): A Novel ACTH-Responsive Gene Overexpressed in Benign Cortisol-Producing Adrenocortical Adenomas J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5130 - 5137. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Aigueperse, P. Val, C. Pacot, C. Darne, E. Lalli, P. Sassone-Corsi, G. Veyssiere, C. Jean, and A. Martinez SF-1 (Steroidogenic Factor-1), C/EBP{beta} (CCAAT/Enhancer Binding Protein), and Ubiquitous Transcription Factors NF1 (Nuclear Factor 1) and Sp1 (Selective Promoter Factor 1) Are Required for Regulation of the Mouse Aldose Reductase-Like Gene (AKR1B7) Expression in Adrenocortical Cells Mol. Endocrinol., January 1, 2001; 15(1): 93 - 111. [Abstract] [Full Text] |
||||
![]() |
E. Brockstedt, M. Peters-Kottig, V. Badock, C. Hegele-Hartung, and M. Lessl Luteinizing Hormone Induces Mouse Vas Deferens Protein Expression in the Murine Ovary Endocrinology, July 1, 2000; 141(7): 2574 - 2581. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Crosas, E. Cederlund, D. Torres, H. Jornvall, J. Farres, and X. Pares A Vertebrate Aldo-keto Reductase Active with Retinoids and Ethanol J. Biol. Chem., May 25, 2001; 276(22): 19132 - 19140. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||